3 ms·
> GSK said it was terminating SRT501 due to [...] the compound itself wasn't patentable. This is the important detail in that story.
by krageon 5y ago
> GSK said it was terminating SRT501 due to [...] the compound itself wasn't patentable.
This is the important detail in that story.